Skip to content
mapperlab
← Dashboard
Stock

CPRX

CATALYST PHARMACEUTICALS, INC.
Health CareBiotechnologyLatest close $316 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
6
27 funds tracked
Ever held
9
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 16, 2021Feb 14, 2022Nov 14, 2024May 15, 2026
Now
6

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$18$31+69%
Citadel Advisors$19$31+62%
AQR Capital Management$19$31+62%
Millennium Management$19$31+62%
Point72 Asset Management re-entered$19$31+62%
D.E. Shaw$23$31+34%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments→ $23+7%
D1 Capital Partners→ $7.58+33%
Maverick Capital→ $7.30+28%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at CATALYST PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
1
Total on file
471
Recent SEC buffer
Most recent
Jun 5, 2026

30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 471 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · CATALYST PHARMACEUTICALS, INC.

Annual figures sourced directly from CATALYST PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$588.99M
FY2025+20% YoY
Net income
$214.33M
FY2025+31% YoY
EPS (diluted)
$1.68
FY2025+28% YoY
Free cash flow(?)
$208.61M
FY2025-13% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for CATALYST PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$31$31+0%
D.E. ShawQ1 2025open$23$31+34%
Two Sigma InvestmentsQ4 2024Q1 2025$22$23+7%
Citadel AdvisorsQ3 2024open$19$31+62%
AQR Capital ManagementQ3 2024open$19$31+62%
Millennium ManagementQ3 2024open$19$31+62%
Point72 Asset ManagementQ3 2024Q4 2024$19$22+13%
Renaissance TechnologiesQ3 2024open$18$31+69%
D1 Capital PartnersQ3 2021Q1 2022$5.71$7.58+33%
Maverick CapitalQ3 2021Q4 2021$5.71$7.30+28%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.